Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that  increases growth hormone and IGF-1 levels. It is an injectable peptide that generates greater natural production of HGH (Human Growth Hormone).  The peptide binds and stimulates human GHRH receptors with similar potency as our own natural GHRH. It does not significantly affect other pituitary hormones in the body.

Tesamorelin is currently the most effective GH releasing hormone on the market. 

Gland Stimulated: Pituitary Gland

What are the benefits?

  • Increases natural productions of HGH (human growth hormone)
  • Increases IGF-1 (Insulin Growth Factor – 1) without altering glucose parameters
  • Reduces triglycerides
  • Reduces Visceral Adipose Tissue (VAT)
  • Reduces Carotid Intima Media Size (cIMT)
  • Improves cognition in adults over the age of 60

What the research shows:

Clinical trials show that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the treatment is discontinued (depending upon the individual).

Tesamorelin  reduces lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in Non-HIV-infected individuals.

According to one clinical study, 10.9 percent of patients who were given Tesamorelin experienced reductions in deep belly fat. These patients suffered from HIV. Reductions in trunk fat, waist size, and waist-to-hip ratios were recorded during the study. However, limbs and abdominal SC fat levels remained the same. During treatment, insulin-like growth factor 1 increases. However, there is no impact on glucose parameters. This drug has limited negative side effects in most patients. However, the results are temporary, as patients who were switched to a placebo lost their improvements. The study lasted six months in total. Overall, visceral fat levels decreased by eighteen percent.


Here is a link to an excerpt from PLOS ONE, an open access peer reviewed resource for clinical data on tesamorelin